ITGAX and myeloid sarcoma: Our findings also suggest that A2A receptor agonist-mediated depletion of CD11c+T-bet+ B cells will alleviate disease burden in other illnesses where CD11c+T-bet+ B cells have been implicated in disease pathogenesis, such as RA, MS, and Sjøgren’s Syndrome14,15,58–61.